Bengaluru: The U.S. Food and Drug Administration plans to ease testing requirements for companies developing biosimilar drugs, Bloomberg News reported, citing an agency official and internal documents ...

Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law PLLC, discusses FDA’s removal of the two-trial requirement marking a significant policy shift and prompting sponsors to ...

March 10, 2026 / Today Technomark Life Sciences ( and MAX BioPharma ( announced their collaboration in the development of MAX BioPharma's oxysterol drug candidate, Oxy210, for targeting ...

Semaglutide has already become more than just a “vanity drug.” Clinical trials like SUSTAIN-6 and FLOW have shown it can slash the risk of kidney disease, reduce major heart attacks, and even lower ...

The 'Most Favored Nation' policy proposes tying U.S. drug prices to those in foreign countries to lower costs. The author argues this policy could reduce patient access to care and slow medical ...

Biologic drugs made up only 5% of prescriptions in the US last year, but accounted for 51% of total drug spending, with many products costing hundreds of thousands of dollars per year. Moreover, only ...

Industry groups have identified upfront costs as a barrier to streamlining U.S. drugmaking. The nonprofit API Innovation Center has a proposed answer for how to tilt finances in favor of investments ...

Artificial intelligence is rapidly inventing new drugs for diseases from Parkinson's disease and antibiotic-resistant superbugs to rare lung conditions.

GH Research PLC is rated a Buy with $280.7M in cash, supporting lead candidate GH001 for Treatment-Resistant Depression. Read more on GHRS stock here.

LOS ANGELES, CA / ACCESS Newswire / March 10, 2026 / Today Technomark Life Sciences ( and MAX BioPharma ( announced their collaboration in the development of MAX ...

For the first time in the decade that homeless mortality has been tracked in Los Angeles County, fewer people have died on the streets and in shelters, the Department of Public Health reported Tuesday ...

BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A ...